ClinicalTrials.gg
Not yet recruitingNCT07307937SONICUMPUpdated Dec 29, 2025

Movement Sonification as an add-on to Immediate Post-event Psychotherapeutic Intervention in the Management of Acute Stress Disorder: a Feasibility and Acceptability Study

An interventional study of The sonification of movement is an act studied in this research. in Acute Stress Disorder Symptoms, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
10th of 12
30 · median 265
Started
2026
with 1 other
No phase
9 of 22
3 open now
Registered
21st of 22
by date

Among the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 with no phase, and was the 21st registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

7 of the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Natural disasters, conflicts, persecution, population displacement, often traumatic migration experiences, and terrorist attacks are all factors that currently expose a significant proportion of the world's population to potentially traumatic events (PTEs). When a person is exposed to a PTE, symptoms of acute stress disorder (ASD) may occur in the immediate aftermath of the PTB, i.e., within the month following the event. These symptoms are dominated by dissociation, which includes depersonalization, i.e., the feeling of being disconnected from one's body. Managing these symptoms can prevent the subsequent onset of post-traumatic stress disorder (PTSD), a serious illness and public health concern. The recommended treatment combines an immediate post-event psychotherapeutic intervention (IPPI) and, where appropriate, medication with anxiolytics from the antihistamine class or antipsychotics

Read the detailed description

In France, IPPI is carried out by the medical-psychological emergency units (CUMP) in each department. Patients are referred to these units by the CUMPs themselves when they are called out by the SAMU (emergency medical service) to the scene of mass accidents (attacks, fires, suicides in public places, etc.), or by departmental doctors and medico-legal emergency services for individual EPTs (sexual or physical assault, etc.). In Seine-Saint-Denis, the CUMP 93 receives 60 to 100 patients per year in the immediate post-traumatic phase.

The purpose of IPPI is to reconnect the traumatic experience with known representations. These interventions have demonstrated effectiveness,although their preventive impact on PTSD remains limited. Movement sonification is an augmented auditory reality technique that transforms a patient's movements into sound through connected wristbands and a speaker system. By enriching bodily perception, this technique may enhance the efficacy of trauma-focused psychotherapies.

This study aims to assess the acceptability and feasibility of using movement sonification in combination with IPPI for the treatment of ASD. It thereby addresses an urgent need for primary prevention of PTSD.

03

Conditions studied

  • Acute Stress Disorder Symptoms

Keywords

  • post-traumatic stress disorder
  • potentially traumatic events
  • transforming the patient's movement into sound information
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 and over
  • Who have experienced a potentially traumatic event (PTE) other than the death of a loved one
  • Who have been referred to the medical-psychological emergency unit (CUMP 93) within one month of the PTE
  • Who are experiencing acute stress disorder (ASD) according to criteria
  • Have health insurance
  • Have signed a written form

Exclusion criteria

Exclusion Criteria:

  • Severe motor impairment rendering the use of sonification technology impractical
  • Deaf, mute, or hearing-impaired patients
  • Adults under guardianship or conservatorship, under judicial protection, or deprived of liberty
  • Suffering from chronic psychotic disorder or bipolar disorder
  • Central neurological disease defined by a medical report (including brain damage, cortical or subcortical atrophy, dementia, stroke, , head trauma, epilepsy, or seizure)
  • Presenting a proven severe risk of suicide
  • Substance use disorder (excluding tobacco)
  • Pregnant or breastfeeding women
  • Participation in another interventional study on ESA
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Sonification

    The sonification of movement is an act studied in this research.

    Device: The sonification of movement is an act studied in this research.

Interventions

  • DeviceThe sonification of movement is an act studied in this research.

    The sonification of movement is an act studied in this research at visit 1, visit 2 and visit 3

06

What researchers measure

Primary outcomes

  1. Evaluate the feasibility of movement sonification in association with IPPI in the treatment of ESA.

    Success rate, defined as an individual adherence rate of at least two sessions completed with movement sonification out of the three sessions planned.

    Time frame: 6 weeks

Secondary outcomes

  1. Dissociative symptoms

    1\) Change in the severity of dissociative symptoms assessed by: 1a) • Clinician-Administered Dissociative States Scale from V1 to V4. A high score on the Clinician-Administered Dissociative States Scale (range 0 to 92) indicates a more severe degree of dissociative symptoms.

    Time frame: 6 weeks

  2. Dissociative symptoms

    1\) Change in the severity of dissociative symptoms assessed by: 1b)• Multidimensional Assessment of Interoceptive Awareness-2 at V1 and V4. A high score on the Multidimensional Assessment of Interoceptive Awareness-2 (range 0 to 160) reflects more developed interoceptive awareness, with an increased ability to recognize and respond adaptively to bodily sensations.

    Time frame: 6 weeks

  3. Agency (sense of control over the external environment)

    Changes in agency assessed by the Fribourg Sense of Agency Scale from V1 to V4. A high score on the Fribourg Sense of Agency Scale (range 13 to 91) is associated with an increased perception of personal control and a stronger integration of conscious action with personal responsibility.

    Time frame: 6 weeks

  4. The overall clinical response

    Change in clinical impression assessed by the Clinical Global Impression-Severity from V1 to V4. The scale ranges from 1 to 7, where a low value indicates no symptoms and 7 indicates a terminal stage disorder.

    Time frame: 6 weeks

  5. The overall clinical response

    Change in clinical impression assessed by Clinical Global Impression-Improvement from V2 to V4. The scale ranges from 1 to 7, where a low value represents significant improvement and 7 indicates considerable deterioration.

    Time frame: 6 weeks

  6. Overall functioning

    Change in overall functioning assessed by the Global Assessment of Functioning from Visit 1 to Visit 4. The Global Assessment of Functioning, scale is used to rate how serious a mental illness may be. It measures how much a person's symptoms affect their day-to-day life on a scale of 0 to 100.A high score on the Global Assessment of Functioning suggests very good or near-normal overall functioning.

    Time frame: 6 weeks

  7. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by the Clinician-Administered Dissociative States Scale. A high score on the Clinician-Administered Dissociative States Scale (range 0 to 92) indicates a more severe degree of dissociative symptoms.

    Time frame: 6 weeks

  8. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by the Multidimensional Assessment of Interoceptive Awareness 2. A high score on the Multidimensional Assessment of Interoceptive Awareness 2 (range 0 to 160) reflects more developed interoceptive awareness, with an increased ability to recognize and respond adaptively to bodily sensations.

    Time frame: 6 weeks

  9. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by Fribourg Sense of Agency Scale. A high score on the Fribourg Sense of Agency Scale (range 13 to 91) is associated with an increased perception of personal control and a stronger integration of conscious action with personal responsibility.

    Time frame: 6 weeks

  10. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by the Global Impression-Severity. The scale ranges from 1 to 7, where a low value indicates no symptoms, and 7 indicates a terminal condition.

    Time frame: 6 weeks

  11. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by the Clinical Global Impression-Improvement. The scale ranges from 1 to 7, where a low value represents a significant improvement, and 7 indicates a considerable deterioration.

    Time frame: 6 weeks

  12. Symptoms associated with ESA in patients with initial symptoms of traumatic dissociation, compared to those without

    Comparison of changes in scale between patients according to the level of dissociation assessed by the Global Assessment Functioning. A high Global Assessment of Functioning score (range from 0 to 100) suggests very good or near-normal overall functioning.

    Time frame: 6 weeks

  13. Evaluate the experience and acceptability of patients and caregivers (qualitative analysis).

    The evaluation of the experience and acceptability will be carried out using a semi-structured interview with the patient at Visit 4

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2026, 11 months later.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 11 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Dec 29, 2025
StartEst.
Jan 15, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07307937
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Jan 15, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Dec 29, 2025

Study contacts

Nicolas BOSC
Contact
nicolas.bosc@aphp.fr
+33 1 48 95 53 74
Sharon Soobben Project Manager
Contact
sharon.soobben@aphp.fr
+33 1 48 95 74 35

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion